Chimeric antigen receptor (CAR) T-cells are currently FDA approved for patients with lymphoma, multiple myeloma, and acute lymphoblastic leukemia. CAR T-cells have revolutionized the therapeutic landscape for Hematologic malignancies. The option of using CAR T-cells for non-cancer related conditions (including autoimmune diseases) is under active investigation in clinical trials. In this session, we will go over the basics of CAR T-cells. To develop CAR T-cells in autoimmune conditions via clinical trials, we will draft a roadmap to apply all the knowledge that we have learned using CAR T-cells in lymphoma.
Learning Objectives:
Summarize the current FDA approved indications for CAR T-cells
Recognize the potential use of CAR T-cells for autoimmune diseases under investigation via clinical trials
Describe possible toxicity associated with CAR T-cells
